Solana CompanyNASDAQ: HSDT

Helius Medical Technologies, Inc. Announces First Clinical Evidence of Positive Long-term Therapeutic Effects of PoNS Therapy® on Gait Deficit Improvement in Multiple Sclerosis from the PoNS® Therapeutic Experience Program Study

· Issued by Solana Company
Read the transcript of Solana (NASDAQ:HSDT) Q1 2026 Earnings Call
Solana's next earnings callSolana (NASDAQ:HSDT) Q3 2026 Earnings Call · Nov 11, 2026 at 4:30 PM ESTRegister

--PoNS Therapeutic Experience Program (PoNSTEP) study demonstrates durable long-term beneficial effects of PoNS Therapy on gait deficit improvement in people with Multiple Sclerosis--

--Statistically significant findings in DGI (Dynamic Gait Index) during Phase 1 and Phase 2 among the 38 subjects who completed the treatment protocol showing a total mean improvement of 5.00 (4.1 to 5.9, p

Solana Company on 6ix

Story so far

Earlier from Solana

Later from Solana

All Solana news releases